|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 30 August 2021, 16:37. The announcement is not marked as price sensitive, and is 13 page(s) in length and 153.69kb in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.002% short sold according to ASIC data. It was ranked the 611th most shorted stock on the ASX. It remains ranked 641st as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| Appendix 4G | 30 August 2021, 16:37 |
| Actinogen Medical FY21 Results- Progressing the Pipeline | 30 August 2021, 16:36 |
| Appendix 4E & Annual Report | 30 August 2021, 16:34 |
| Actinogen completes global patent family grant | 23 August 2021, 9:19 |
You must be logged in to post a reply.
Actinogen Medical 